🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. lipegfilgrastim

    Teva Pharma GmbH

    Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

    phase 3 small molecule completed

    1 trial

  2. lixisenatide AVE0010

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  3. mRNA-1010

    Moderna Biotech Spain

    Seasonal Influenza

    phase 3 mab completed

    1 trial

  4. mRNA-1647, Sodium Chloride 0.9%, Solution for Injection

    Moderna Biotech Spain

    Cytomegalovirus Infection (CMV)

    phase 3 small molecule active

    1 trial

  5. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  6. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. mannitol and microcrystalline cellulose, Tolebrutinib

    Genzyme Europe B.V.

    Primary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  8. masitinib, Placebo to 200mg masitinib, Placebo to 100mg masitinib, masitinib

    AB Science

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  9. masitinib, Placebo to 200mg masitinib, Placebo to 100mg masitinib, masitinib

    AB Science

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  10. matched placebo for test product, Duvakitug

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  11. migalastat HCl 150 mg

    AMICUS THERAPEUTICS PTY LTD

    Fabry Disease

    phase 3 small molecule completed

    1 trial

  12. nintedanib, Nintedanib, nintedanib

    Boehringer Ingelheim

    Childhood Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  13. normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab

    BeiGene

    Locally advanced, unresectable, or metastatic non small cell lung cancer

    phase 3 small molecule active

    1 trial

  14. oral estradiol 1.0 mg

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    1 trial

  15. peginterferon alfa-2b (SCH 54031)

    Universal Integrated

    Hepatitis C, Chronic

    phase 3 mab completed

    1 trial

  16. placebo ketamine inj prep, KETAMINE RENAUDIN 10 mg/ml, solution injectable

    ISTA Pharma Limited

    Traumatism

    phase 3 small molecule active

    1 trial

  17. placebo of metformine, METFORMINE VIATRIS 500 mg, comprimé dispersible

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  18. probiotic strain Bb-12

    United Therapeutics Europe Ltd

    Infections, Respiratory

    phase 3 other completed

    1 trial

  19. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT THERAPEUTICS INC

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  20. riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases.

    phase 3 small molecule active

    1 trial

  21. riliprubart placebo, solution for injection in prefilled pen (PFP), riliprubart placebo, solution for injection in vial, riliprubart, riliprubart

    Sanofi-aventis Healthcare Pty Ltd

    Polyneuropathy, Inflammatory Demyelinating, Chronic

    phase 3 small molecule active

    1 trial

  22. riliprubart, -, riliprubart placebo solution for injection in prefilled pen, placebo matching IVIg, riliprubart, riliprubart placebo solution for injection in vial, -

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 3 small molecule active

    1 trial

  23. rilonacept 160 mg

    Regeneron UK Limited

    Familial Cold Autoinflammatory Syndrome (FCAS)

    phase 3 small molecule completed

    1 trial

  24. risankizumab placebo, Risankizumab, ABBV-066 / Risankizumab, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources